Literature DB >> 21977007

Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.

Benjamin Ray Miller1, Ilya Bezprozvanny.   

Abstract

Huntington's disease (HD) is a noncurable and progressive autosomal-dominant neurodegenerative disorder that results from a polyglutamine expansion in the amino-terminal region of the huntingtin protein. The generation of rodent HD models has revealed that cellular dysfunction, rather than cell death alone, occurs early in the disease progression, appearing even before overt symptom onset. Much evidence has now established that dysfunction of the corticostriatal circuit is key to HD symptomology. In this article, we summarize the most current findings that implicate glutamate, dopamine and calcium signaling in this system and discuss how they work in concert to disrupt corticostriatal function. In addition, we highlight therapeutic strategies related to altered corticostriatal signaling in HD.

Entities:  

Year:  2010        PMID: 21977007      PMCID: PMC3184508          DOI: 10.2217/fnl.10.41

Source DB:  PubMed          Journal:  Future Neurol        ISSN: 1479-6708


  205 in total

1.  Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.

Authors: 
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

Review 2.  Neuronal calcium signaling.

Authors:  M J Berridge
Journal:  Neuron       Date:  1998-07       Impact factor: 17.173

3.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

4.  Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.

Authors:  Amaal J Starling; Véronique M André; Carlos Cepeda; Marianne de Lima; Scott H Chandler; Michael S Levine
Journal:  J Neurosci Res       Date:  2005-11-01       Impact factor: 4.164

5.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

6.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

7.  Presynaptic modulation by GABAB receptors of glutamatergic excitation and GABAergic inhibition of neostriatal neurons.

Authors:  E S Nisenbaum; T W Berger; A A Grace
Journal:  J Neurophysiol       Date:  1992-02       Impact factor: 2.714

8.  Riluzole in Huntington's disease: a 3-year, randomized controlled study.

Authors:  G Bernhard Landwehrmeyer; Bruno Dubois; Justo Garcia de Yébenes; Berry Kremer; Wilhelm Gaus; Peter H Kraus; Horst Przuntek; Michel Dib; Adam Doble; Wilhelm Fischer; Albert C Ludolph
Journal:  Ann Neurol       Date:  2007-09       Impact factor: 10.422

9.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

10.  Widespread expression of Huntington's disease gene (IT15) protein product.

Authors:  A H Sharp; S J Loev; G Schilling; S H Li; X J Li; J Bao; M V Wagster; J A Kotzuk; J P Steiner; A Lo
Journal:  Neuron       Date:  1995-05       Impact factor: 17.173

View more
  30 in total

1.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

2.  Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

Authors:  Eric A Horne; Jonathan Coy; Katie Swinney; Susan Fung; Allison E T Cherry; William R Marrs; Alipi V Naydenov; Yi Hsing Lin; Xiaocui Sun; C Dirk Keene; Eric Grouzmann; Paul Muchowski; Gillian P Bates; Ken Mackie; Nephi Stella
Journal:  Eur J Neurosci       Date:  2012-11-21       Impact factor: 3.386

3.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

4.  Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Authors:  Carissa D Winland; Nora Welsh; Alberto Sepulveda-Rodriguez; Stefano Vicini; Kathleen A Maguire-Zeiss
Journal:  Eur J Neurosci       Date:  2017-10-10       Impact factor: 3.386

Review 5.  Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.

Authors:  Ilya Bezprozvanny
Journal:  Neurochem Res       Date:  2011-01-06       Impact factor: 3.996

6.  Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington's disease.

Authors:  Robert M Bragg; Sydney R Coffey; Rory M Weston; Seth A Ament; Jeffrey P Cantle; Shawn Minnig; Cory C Funk; Dominic D Shuttleworth; Emily L Woods; Bonnie R Sullivan; Lindsey Jones; Anne Glickenhaus; John S Anderson; Michael D Anderson; Stephen B Dunnett; Vanessa C Wheeler; Marcy E MacDonald; Simon P Brooks; Nathan D Price; Jeffrey B Carroll
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

Review 7.  Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Authors:  Mark S Moehle; P Jeffrey Conn
Journal:  Mov Disord       Date:  2019-06-18       Impact factor: 10.338

8.  Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease.

Authors:  Sydney R Coffey; Robert M Bragg; Shawn Minnig; Seth A Ament; Jeffrey P Cantle; Anne Glickenhaus; Daniel Shelnut; José M Carrillo; Dominic D Shuttleworth; Julie-Anne Rodier; Kimihiro Noguchi; C Frank Bennett; Nathan D Price; Holly B Kordasiewicz; Jeffrey B Carroll
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

9.  Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease.

Authors:  Benjamin R Miller; Jenelle L Dorner; Kendra D Bunner; Thomas W Gaither; Emma L Klein; Scott J Barton; George V Rebec
Journal:  J Neurochem       Date:  2012-03-28       Impact factor: 5.372

10.  Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.

Authors:  Jun Wu; Daniel Ryskamp; Lutz Birnbaumer; Ilya Bezprozvanny
Journal:  J Huntingtons Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.